Table 1.
Clinical parameters and their relationship with CRP immunoreactivity
| Clinical parameter | CRP grade 0, 1, 2 | CRP grade 3 | p-value |
|---|---|---|---|
| Gender | .019 | ||
| Male | 150 (67.0) | 20 (8.9) | |
| Female | 44 (19.6) | 10 (4.5) | |
| Age (yr) | .054 | ||
| < 60 | 123 (54.9) | 22 (9.8) | |
| ≥ 60 | 71 (31.7) | 8 (3.6) | |
| Tumor size (cm) | .110 | ||
| < 5 | 138 (61.6) | 19 (8.5) | |
| ≥ 5 | 56 (25.0) | 11 (4.9) | |
| Serum AFP (ng/mL) | .125 | ||
| < 400 | 141 (62.9) | 24 (10.7) | |
| ≥ 400 | 53 (23.6) | 6 (2.7) | |
| BCLC stage | < .001 | ||
| A | 185 (82.6) | 26 (11.6) | |
| B | 9 (4.0) | 4 (1.8) | |
| Etiology | .096 | ||
| HBV | 139 (62.1) | 23 (10.3) | |
| HCV | 20 (8.9) | 1 (0.4) | |
| NBNC | 35 (15.6) | 6 (2.7) | |
| Fibrosis stage (Batts-Ludwig) | .454 | ||
| Stage 1, 2 | 39 (17.4) | 7 (3.1) | |
| Stage 3, 4 | 155 (69.2) | 23 (10.3) | |
| Microvascular invasion | .983 | ||
| Not identified | 136 (60.7) | 21 (9.4) | |
| Present | 58 (25.9) | 9 (4.0) | |
| Tumor number | < .001 | ||
| <3 | 185 (82.6) | 26 (11.6) | |
| ≥3 | 9 (4.0) | 4 (1.8) | |
| Edmondson-Steiner grade (worst) | .814 | ||
| Grade 1, 2 | 67 (29.9) | 10 (4.5) | |
| Grade 3, 4 | 127 (56.7) | 20 (8.9) | |
| Edmondson-Steiner grade (most) | .241 | ||
| Grade 1, 2 | 128 (57.1) | 18 (8.0) | |
| Grade 3, 4 | 66 (29.5) | 12 (5.4) | |
| Capsular invasion | .492 | ||
| Absent | 156 (69.6) | 25 (11.2) | |
| Present | 38 (17.0) | 5 (2.2) | |
| Early recurrence | .098 | ||
| Absent | 114 (50.9) | 15 (6.7) | |
| Occurs | 80 (35.7) | 15 (6.7) |
Values are presented as number (%).
CRP, C-reactive protein; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCB, hepatitis C virus; NBNC, non-B, non-C hepatocellular carcinoma.